Literature DB >> 2422189

Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography.

L D Kissinger, N L Stemm.   

Abstract

A reversed-phase high-performance liquid chromatography (HPLC) system was developed for the determination of the antineoplastic agents cytarabine and azacitidine. Separations were performed on an octadecylsilane column with a mobile phase of methanol-phosphate buffer pH 7.0 (5:95). The assay methods are suitable for bulk drugs and sterile powder formulations of the agents. Specificity in the presence of analogues and decomposition products was demonstrated. UV spectra of the components of interest were obtained in the HPLC effluent, and appropriate wavelengths were employed for the various analytes. Samples of azacitidine in various solutions were analyzed as a function of time by HPLC to determine the three first-order constants associated with its decomposition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422189     DOI: 10.1016/s0021-9673(01)87101-6

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine.

Authors:  Nicole M Anders; Teresia M Wanjiku; Ping He; Nilofer S Azad; Michelle A Rudek
Journal:  Biomed Chromatogr       Date:  2015-08-17       Impact factor: 1.902

2.  Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Authors:  Nicole M Anders; Jianyong Liu; Teresia Wanjiku; Hugh Giovinazzo; Jianya Zhou; Ajay Vaghasia; William G Nelson; Srinivasan Yegnasubramanian; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-03-21       Impact factor: 3.205

3.  Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.

Authors:  Sieta P Rao; Markus P Rechsteiner; Christoph Berger; Jürg A Sigrist; David Nadal; Michele Bernasconi
Journal:  Mol Cancer       Date:  2007-01-10       Impact factor: 27.401

4.  Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.

Authors:  M D Reed; C S Tellez; M J Grimes; M A Picchi; M Tessema; Y S Cheng; T H March; P J Kuehl; S A Belinsky
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

5.  AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

Authors:  A Unnikrishnan; A N Q Vo; R Pickford; M J Raftery; A C Nunez; A Verma; L B Hesson; J E Pimanda
Journal:  Leukemia       Date:  2017-11-29       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.